There is evidence that chronic myelogenous leukemia leukocytes (CMLL) may synthesize B12BP. Our prior studies suggested that intact, living intravascular G synthesize and release such protein into extracellular compartments in vivo.
INTRODUCTION
It has been known for more than a decade (1) that the sera of patients with chronic myelogenous leukemia .(CML) contain high levels of a vitamin B2-lbinding proReceived for publication 1 June 1970. tein with alpha-electrophoretic motility. This led various investigators (2) (3) (4) (5) to study granulocytes in relation to their capacity to bind vitamin Bi when added in vitro.
The binding capacity for additional vitamin B12 has been reported as 0.06-0.08 ng/107 cells (3), 1.5 ng/107 cells (4) , and 8.9 ng/107 cells (5) . In 1966, Simons and Weber (6) reported that human granulocytes in vitro are capable of synthesizing a protein with elution properties similar to that of the leukocyte vitamin B1n binder. In recent studies from our laboratory,1 we have found an excellent correlation between the serum unsaturated vitamin B2-binding capacity and the total blood granulocyte pool. These studies supported the concept that at least part of the serum B12-binding proteins derive from intact, intravascular granulocytes. The studies to be described were undertaken in an attempt to throw further light on this hypothesis.
Our observations support the concept that the leukocyte vitamin Bu-binding protein is actively secreted by granulocytes. Subcellular fractionation studies of human granulocytes demonstrate that most of this protein is associated with the granular layer.
METHODS

Gel filtration studies. Sephadex G-200 was obtained from
Pharmacia Fine Chemicals, Piscataway, N. J. A 2.5 X 85 cm column was packed as described by Flodin (7) . The buffer used was 0.075 M Tris, containing 0.075 M phosphate, 1 M NaCl, and 0.02%o Na azide.
Granulocytes obtained from a patient with CML by the dextran sedimentation-hypotonic shock method (8) Aliquots of the cell suspension were added to 10-ml vacutainer tubes followed by the appropriate inhibitor or stimulator. In the experiments carried out at 370 or 4VC, the tubes were equilibrated to the desired temperature before adding the cell suspension. The average nucleated cell count in the final suspension was 50,000 cells/mm3. After incubation, the tubes were centrifuged at 3000 rpm for 4 min in a refrigerated centrifuge. The supernatants were then carefully removed with a Pasteur pipette.
The vitamin B1,-binding capacity (B12BP) was determined in aliquots of the supernates by coated charcoal assay (9) .
In that procedure an excess of 'CoB=, (specific activity 10 /ACi/,ug; E. R. Squibb & Sons, New York) was added to each fraction and the tubes incubated at room temperature for 30 min. The excess vitamin Bu was removed by the addition of 2 ml of a hemoglobin-coated charcoal suspension and the radioactivity in the supernates was measured in an automatic Picker gamma counter (Picker X-Ray Corp., Cleveland, Ohio). Results were expressed as net counts per minute of 'CoB12 in supernates.
Leucine-'H with a specific activity of 5.2 Ci/mmoles per liter was obtained from Tracerlab Div., Richmond, Calif. In the experiments where release of radioactive protein into the media was measured, the cell suspension was preincubated with 2 /ACi/ml of packed cells of leucine-3H for 1 hr at 370C, the cells were washed twice with TH, and the cell suspension was resuspended in THA. At different time intervals, the tubes were centrifuged at 3000 rpm for 4 min in a refrigerated centrifuge and the supernates were removed carefully with a Pasteur pipette. 02 ml of 50 mg/ml of bovine serum albumin (Armour Industrial Chemical Co., Chicago, Ill.) was added to aliquots of the supernates followed by 1 ml of 50% trichloroacetic acid (TCA). The tubes were left overnight at 40C and the next morning the precipitate was washed twice with 3 ml of 10%o TCA and dissolved in 1.0 ml of Hyamine (Rohm and Haas Co., Philadelphia, Pa.). Afer adding 15 ml of scintillation fluid (10), the vials were counted in a Picker Liquimat 330 liquid scintillation counter. Results were expressed as net counts per minute of leucine-'H.
2 At the time the blood was obtained, this 43 yr old Negro male (C. S.) had a serum B1, level of 448 pg/ml, despite the fact that his only treatment for pernicious anemia was 5 Ag of B1, intramuscularly 1 month earlier. We are following him in an attempt to determine whether his B12 deficiency is keeping his CML from worsening.
In the studies with iododeoxyuridine-'I, 0.2 ml of 50 mg/ml of bovine serum albumin was also added to the supernates followed by precipitation with TCA. Precipitate was then counted in a gamma counter.
When incorporation of leucine-'H by leukocytes was studied, the red cells in the suspension were removed by hypotonic shock lysis and the resultant white cell button was precipitated with 10% TCA at 40C. The precipitate was washed twice with 10% TCA and then dissolved in 1 ml of Hyamine. 15 ml of scintillation fluid was then added and the vials were counted in a liquid scintillation counter. Results were expressed as net counts per minute of leucine-3H.
In the studies with iododeoxyuridine-n'I, the cell buttons were counted after hypotonic shock lysis and TCA precipi- Incorporation and release into the medium of iododeoxyuridine-"'I. Fig. 6 shows the increasing incorporation of iododeoxyuridine-"I into leukocytes over a 5 hr period. As can be seen, very little acid insoluble radioactivity is released into the medium over the study period. (Fig. 1) (13, 14) , it has been suggested that granulocytes are the source of this serum protein (5) . This concept is further supported by the presence of high levels of this protein in the sera of patients with CML (1) and the fact that granulocytes in vitro synthesize a protein with elution properties similar to the leukocyte B,2 binder (5).
Recent studies1 from our laboratory have demonstrated a better correlation between the serum unsaturated vitamin Bur-binding capacity (UB12BC) and the total blood granulocyte pool, than that observed between the UBI2BC and the granulocyte turnover rate. These and the current studies support the concept that at least part of the serum Bir-binding proteins are actively secreted by intact, intravascular granulocytes rather than being just part of the debris from destroyed granulocytes.
In the current studies, in vitro release of the leukocyte vitamin B,2 binder proved to be temperature dependent (released at 370C but not at 4VC) and inhibited by N-ethylmaleimide, a sulfhydryl inhibitor known to inhibit the release of beta-glucuronidase (induced by calcium in the leukocidin-treated rabbit granulocyte) (15) (16) and granulocytes (17) , also increases the release of B,2BP. This stimulation is temperature dependent and, interestingly, is not affected by preincubation with n-ethylmaleimide (Fig. 3) . Since 20% of the cells become Trypan blue positive at the end of 1 hr, when exposed to the concentration of 48/80 used in our experiments, it is possible the effect of this compound upon granulocytes, at this concentration, is toxic.
Cycloheximide, a known inhibitor of protein synthesis, suppresses incorporation of leucine-3H by leukemic leukocytes almost completely (Fig. 4) . At the same concentration it exerts no effect upon the release of B12BP (Fig. 2) or upon the release of acid insoluble radioactivity by leukocytes prelabeled with leucine-2H (Fig. 5) . Similar findings have been recently reported (18) for the release of amylase by parotid gland slices in vitro.
Since the release of B=BP or acid insoluble radioactivity in our system could be a reflection of cell disruption rather than or in addition to an active secretory process, studies were undertaken using labeled iododeoxyuridine as a precursor of leukocyte nucleoproteins. Incorporation of the precursor was continuous at 370 C over a 5 hr period, but there was no significant increase in the labeled nucleoprotein (acid insoluble radioactivity) present in the media (Fig. 6 ). These findings provide evidence against significant cell disruption, and support active secretion of B12BP from storage depots within the cell (as opposed to secretion of continuously produced B12BP).
A variety of substances (phagocytin, hyaluronidase, lyzozyme, ribonuclease, deoxyribonuclease, beta-glucuronidase, histamine) have been shown to be actively secreted by leukocytes in vitro (19) , in response to different stimuli. These compounds have been shown by subcellular fractionation studies to originate from granules within the leukocytes. Our studies demonstrate that the BW2BP is also predominantly found in the granular layer of granulocytes (Fig. 7) , with an excellent correlation observed between its subcellular distribution and that of acid phosphatase (Fig. 8) . The presence of significant B,2BP (and acid phosphatase) in the lower layers of the 78,000 g button could represent either contamination of this fraction with the granular layer or heterogeneity of the granules resulting in different sedimentation velocities. Such heterogeneity has been recently described from several laboratories (20) (21) (22) . Should such prove correct, then we would expect that the 78,000 g button will prove to contain miore granules containing B12BP than granules containing acid phosphatase.
Whether the B51BP is an enzyme (13) or one of the proteins related to specific types of granules (21) remains undetermined.
Thus, the current studies provide further evidence that granulocytes are secretory as well as phagocytic cells. This would help explain the apparent correlation of Bi2BP with total body granulocyte pool in hypo-and hyperleukocytic states (23, 24) . A preliminary report of some of these studies has recently been presented (25) .
